• Milestone Pharma
    Milestone Pharma
    • About Us
      • Leadership Team
      • Board of Directors
      • Careers
      • Contact Us
    • Areas of Focus
      • Paroxysmal supraventricular tachycardia (PSVT)
      • Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
    • Products
      • CARDAMYST™
    • Pipeline
      • Etripamil
      • Publications
      • Clinical Trials & Patient Access
      • FAQ
    • Investors & Media
      • News & Events
      • Stock Information
      • Financial Information
      • Corporate Governance
      • Investor Resources
Milestone Pharma
Close

MONTREAL and CHARLOTTE, N.C. , Nov. 21, 2023 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference on Tuesday, November 28, 2023 , at 10:30 a.m.

Share This Story, Choose Your Platform!

Related Posts

  • 0

    Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia

  • 0

    Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation

  • 0

    Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster

  • 0

    First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)

PreviousMilestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesNext Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Careers | Contact Us | Privacy Policy | Consumer Health Data Privacy Policy | Terms of Use | California Compliance Program Declaration
© Milestone Pharmaceuticals USA, Inc. All Rights Reserved. PM-etri-00010-2 12/25

Our website content is tailored by geographical region to comply with local regulatory requirements. Please select which country’s site you’d like to visit.